Research and Markets: Global Strategic Business Report on Anti-Obesity Drugs with Most Recent Key Developments and Future Products in the Pipleline

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/c1bb7f/antiobesity_drugs) has
announced the addition of the "Anti-Obesity Drugs - Global Strategic Business
Report" report to their offering.

This report analyzes the worldwide markets for Anti-Obesity Drugs in Millions of
US$. The report provides separate comprehensive analytics for the US, Europe,
and Rest of World. Annual forecasts are provided for each region for the period
of 2005 through 2015.

The report profiles 85 companies including many key and niche players worldwide
such as

* Abbott Laboratories (US)
* Alizyme Plc (UK)
* Amylin Pharmaceuticals, Inc. (US)
* AstraZeneca Plc (UK)
* F. HOFFMANN-LA ROCHE LTD. (Switzerland)
* GlaxoSmithKline Plc (UK)
* Sanofi-Aventis SA (France)
* SuperGen, Inc. (USA)
* Takeda Pharmaceutical Company Limited (Japan)
* VIVUS, Inc. (US)

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select
online sources.

Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
II. Executive Summary
1. Industry Overview
2. Competition
3. Obesity - An Introduction
4. Obesity Treatment
5. Anti-Obesity Drugs- An Insight
6. Recent Clinical Trials
7. Product Approvals/Launches
8. Recent Industry Activity
9. Focus on Select Players
10. Global Market Perspective
III. MARKET
1. The United States
2. Europe
3. Rest of World
IV. COMPETITIVE LANDSCAPE

For more information visit
http://www.researchandmarkets.com/research/c1bb7f/antiobesity_drugs

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009